iRhythm Technologies, Inc. Overview
Pro stress-test →iRhythm is a digital healthcare company engaged in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias. The company provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders, pioneering the shift from traditional bulky monitors to wireless patch-based systems.
Strategic Profile
Pro stress-test →iRhythm reported its sixth consecutive quarter of over 20% growth, driven primarily by its core Zio Monitor heart monitoring business, with improving profitability supported by gross margin gains and lower SG&A burden. AI-driven efficiencies and new product launches are expected to drive further margin gains, while international and innovative channel expansion remain key growth areas.
Competitive Landscape
Pro stress-test →iRhythm competes in the ambulatory cardiac monitoring market against established medical device companies and newer digital health players. Primary competitors include traditional cardiac monitoring providers (Holter monitors, event monitors) and emerging wearable ECG platforms. The company's wireless patch technology and integrated data analytics create differentiation versus legacy products, with expanding Medicare coverage improving competitive positioning.
Industry Context
iRhythm Technologies, Inc. operates in Medical Devices & Diagnostics - Cardiac Monitoring.
Key facts
Founded: 2006 · Headquarters: San Francisco, US · Employees: Unknown · Revenue: $747.1M (trailing 12 months) · Market cap: ~$7.5B (estimated as of June 2026)